Does the media favor ADPT or RVTY?

In the previous week, Adaptive Biotechnologies had 13 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 3 mentions for Revvity. Revvity's average media sentiment score of 0.51 beat Adaptive Biotechnologies' score of 0.31 indicating that Revvity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Revvity 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MEDP or ADPT?

In the previous week, Adaptive Biotechnologies had 10 more articles in the media than Medpace. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 6 mentions for Medpace. Medpace's average media sentiment score of 0.67 beat Adaptive Biotechnologies' score of 0.31 indicating that Medpace is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ICLR or ADPT?

In the previous week, Adaptive Biotechnologies had 8 more articles in the media than Icon. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 8 mentions for Icon. Icon's average media sentiment score of 0.72 beat Adaptive Biotechnologies' score of 0.31 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADPT or TXG?

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than 10x Genomics. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 12 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.54 beat Adaptive Biotechnologies' score of 0.31 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 10x Genomics 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Adaptive Biotechnologies (ADPT) Competitors

$26.49 +0.40 (+1.53%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$26.13 -0.36 (-1.34%)

As of 10/9/2026 07:30 PM Eastern

Compare

ADPT vs. RVTY, MEDP, CRL, ICLR, and TXG

Should you buy Adaptive Biotechnologies stock or one of its competitors? Adaptive Biotechnologies's main competitors and comparable companies include Revvity (RVTY), Medpace (MEDP), Charles River Laboratories International (CRL), Icon (ICLR), and 10x Genomics (TXG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Adaptive Biotechnologies compare to Revvity?

Adaptive Biotechnologies (NASDAQ:ADPT) and Revvity (NYSE:RVTY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, risk, institutional ownership and dividends.

Adaptive Biotechnologies currently has a consensus target price of $28.94, indicating a potential upside of 9.24%. Revvity has a consensus target price of $120.50, indicating a potential downside of 21.86%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Adaptive Biotechnologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Revvity	0 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.26

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 0.9% of Revvity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Adaptive Biotechnologies has a beta of 2.09, indicating that its share price is 109% more volatile than the broader market. Comparatively, Revvity has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 13 more articles in the media than Revvity. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 3 mentions for Revvity. Revvity's average media sentiment score of 0.51 beat Adaptive Biotechnologies' score of 0.31 indicating that Revvity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revvity	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	15.26	-$59.50M	-$0.41	N/A
Revvity	$2.86B	6.02	$241.20M	$2.10	73.43

Revvity has a net margin of 8.16% compared to Adaptive Biotechnologies' net margin of -20.73%. Revvity's return on equity of 8.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Revvity	8.16%	8.34%	5.01%

Summary

Adaptive Biotechnologies and Revvity tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Medpace?

Medpace (NASDAQ:MEDP) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

In the previous week, Adaptive Biotechnologies had 10 more articles in the media than Medpace. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 6 mentions for Medpace. Medpace's average media sentiment score of 0.67 beat Adaptive Biotechnologies' score of 0.31 indicating that Medpace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medpace has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Medpace presently has a consensus target price of $607.73, suggesting a potential downside of 0.71%. Adaptive Biotechnologies has a consensus target price of $28.94, suggesting a potential upside of 9.24%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Medpace has a net margin of 17.67% compared to Adaptive Biotechnologies' net margin of -20.73%. Medpace's return on equity of 110.15% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

78.0% of Medpace shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Medpace has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	6.75	$451.12M	$17.06	35.88
Adaptive Biotechnologies	$276.98M	15.26	-$59.50M	-$0.41	N/A

Summary

Medpace beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

In the previous week, Charles River Laboratories International had 7 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 23 mentions for Charles River Laboratories International and 16 mentions for Adaptive Biotechnologies. Charles River Laboratories International's average media sentiment score of 0.65 beat Adaptive Biotechnologies' score of 0.31 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Charles River Laboratories International presently has a consensus price target of $300.11, indicating a potential downside of 0.70%. Adaptive Biotechnologies has a consensus price target of $28.94, indicating a potential upside of 9.24%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Adaptive Biotechnologies has lower revenue, but higher earnings than Charles River Laboratories International. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.59	-$144.34M	-$4.85	N/A
Adaptive Biotechnologies	$276.98M	15.26	-$59.50M	-$0.41	N/A

Charles River Laboratories International has a net margin of -5.96% compared to Adaptive Biotechnologies' net margin of -20.73%. Charles River Laboratories International's return on equity of 15.75% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Summary

Charles River Laboratories International beats Adaptive Biotechnologies on 10 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Icon?

Icon (NASDAQ:ICLR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Adaptive Biotechnologies had 8 more articles in the media than Icon. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 8 mentions for Icon. Icon's average media sentiment score of 0.72 beat Adaptive Biotechnologies' score of 0.31 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Icon presently has a consensus target price of $174.73, suggesting a potential upside of 6.43%. Adaptive Biotechnologies has a consensus target price of $28.94, suggesting a potential upside of 9.24%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Icon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Icon has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.52	$229.34M	$4.26	38.54
Adaptive Biotechnologies	$276.98M	15.26	-$59.50M	-$0.41	N/A

Icon has a net margin of 3.99% compared to Adaptive Biotechnologies' net margin of -20.73%. Icon's return on equity of 8.02% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Icon has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

95.6% of Icon shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 44.0% of Icon shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Icon beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to 10x Genomics?

Adaptive Biotechnologies (NASDAQ:ADPT) and 10x Genomics (NASDAQ:TXG) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Adaptive Biotechnologies currently has a consensus target price of $28.94, suggesting a potential upside of 9.24%. 10x Genomics has a consensus target price of $58.60, suggesting a potential downside of 27.34%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Adaptive Biotechnologies is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.28

Adaptive Biotechnologies has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 1.99, meaning that its stock price is 99% more volatile than the broader market.

10x Genomics has higher revenue and earnings than Adaptive Biotechnologies. 10x Genomics is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	15.26	-$59.50M	-$0.41	N/A
10x Genomics	$642.82M	16.35	-$43.54M	-$0.59	N/A

10x Genomics has a net margin of -12.18% compared to Adaptive Biotechnologies' net margin of -20.73%. 10x Genomics' return on equity of -9.33% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
10x Genomics	-12.18%	-9.33%	-7.30%

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than 10x Genomics. MarketBeat recorded 16 mentions for Adaptive Biotechnologies and 12 mentions for 10x Genomics. 10x Genomics' average media sentiment score of 0.54 beat Adaptive Biotechnologies' score of 0.31 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
10x Genomics	2 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

10x Genomics beats Adaptive Biotechnologies on 8 of the 15 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.23B	$10.58B	$7.25B	$13.30B
Dividend Yield	N/A	1.45%	2.52%	22.58%
P/E Ratio	N/A	32.42	275.29	26.14
Price / Sales	15.26	106.15	576.85	85.23
Price / Cash	N/A	27.28	76.96	53.71
Price / Book	18.02	6.48	11.22	6.33
Net Income	-$59.50M	$56.67B	$3.50B	$382.15M
7 Day Performance	-6.56%	-1.01%	-0.89%	-1.40%
1 Month Performance	9.46%	9.16%	-4.02%	-3.35%
1 Year Performance	74.62%	32.19%	7.13%	1.49%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	2.5708 of 5 stars	$26.49 +1.5%	$28.94 +9.2%	+74.6%	$4.23B	$276.98M	N/A	624	Insider Trade
RVTY Revvity	2.4008 of 5 stars	$157.14 +3.7%	$116.57 -25.8%	+74.5%	$16.91B	$2.86B	74.83	11,000	Analyst Forecast
MEDP Medpace	2.9119 of 5 stars	$620.51 +3.5%	$602.27 -2.9%	+22.1%	$16.73B	$2.78B	36.37	6,200	Analyst Forecast
CRL Charles River Laboratories International	2.3147 of 5 stars	$310.84 +7.1%	$300.11 -3.5%	+80.8%	$14.84B	$4.00B	N/A	19,700	Insider Trade Analyst Revision
ICLR Icon	2.9661 of 5 stars	$168.33 +3.9%	$172.40 +2.4%	-10.5%	$12.89B	$8.29B	39.51	40,100	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, MEDP, CRL, ICLR, and TXG

How does Adaptive Biotechnologies compare to Revvity?

Summary

How does Adaptive Biotechnologies compare to Medpace?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Summary

How does Adaptive Biotechnologies compare to Icon?

Summary

How does Adaptive Biotechnologies compare to 10x Genomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, MEDP, CRL, ICLR, and TXG

How does Adaptive Biotechnologies compare to Revvity?

Do analysts recommend ADPT or RVTY?

Do institutionals & insiders believe in ADPT or RVTY?

Which has more risk & volatility, ADPT or RVTY?

Does the media favor ADPT or RVTY?

Which has higher valuation and earnings, ADPT or RVTY?

Is ADPT or RVTY more profitable?

Summary

How does Adaptive Biotechnologies compare to Medpace?

Does the media prefer MEDP or ADPT?

Which has more volatility & risk, MEDP or ADPT?

Do analysts rate MEDP or ADPT?

Is MEDP or ADPT more profitable?

Do institutionals & insiders hold more shares of MEDP or ADPT?

Which has higher earnings and valuation, MEDP or ADPT?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Do institutionals & insiders believe in CRL or ADPT?

Which has more volatility & risk, CRL or ADPT?

Does the media refer more to CRL or ADPT?

Do analysts rate CRL or ADPT?

Which has preferable valuation and earnings, CRL or ADPT?

Is CRL or ADPT more profitable?

Summary

How does Adaptive Biotechnologies compare to Icon?

Does the media favor ICLR or ADPT?

Do analysts rate ICLR or ADPT?

Which has preferable valuation and earnings, ICLR or ADPT?

Is ICLR or ADPT more profitable?

Which has more risk and volatility, ICLR or ADPT?

Do insiders & institutionals believe in ICLR or ADPT?

Summary

How does Adaptive Biotechnologies compare to 10x Genomics?

Do analysts recommend ADPT or TXG?

Which has more volatility & risk, ADPT or TXG?

Which has stronger earnings & valuation, ADPT or TXG?

Is ADPT or TXG more profitable?

Does the media prefer ADPT or TXG?

Do insiders & institutionals hold more shares of ADPT or TXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools